Two Phase III Studies Evaluating Bevacizumab in Metastatic Breast Cancer Presented At ESMO

Two Phase III Studies Evaluating Bevacizumab in Metastatic Breast Cancer Presented At ESMO
shutterstock_92514937The results of two randomised phase III clinical trials in HER2-negative metastatic breast cancer were presented at the European Society for Medical Oncology (ESMO) 2014 meeting, Madrid, Spain. Dr. Joseph Gligorov of the Medical Oncology Department, Tenon University Hospital, Paris, France, presented results on the randomized Phase III IMELDA study, which evaluated the efficacy and safety of maintenance bevacizumab, a monoclonal antibody that inhibits angiogenesis, with or without capecitabine after initial first-line bevacizumab plus docetaxel. The results demonstrated that combining bevacizumab with first-line chemotherapy significantly improved progression free survival in HER2-negative breast cancer patients with locally recurrent and/or metastatic breast cancer. The researchers wanted to determine if switching to a more tolerable chemotherapy with a different mechanism of action while continuing VEGF inhibition could be more effective. As such, after 3‒6 cycles of bevacizumab/docetaxel, patients who did not suffer from disease progression were treated with bevacizumab alone or with bevacizumab/capecitabine until disease progression. The results demonstrated that in groups of patients who benefit from first-line bevacizumab therapy, the continuous administration of bevacizuamb with capecitabine
Subscribe or to access all post and page content.